BCL2 and diffuse large B-cell lymphoma: reported that among 84 patients with stage I/II DLBCL who received immunochemotherapy followed by consolidative RT, double expression of MYC and BCL2 was detected in 16 (19%) patients; and this double expression was not associated with the inferior PFS (88% vs. 100%, p = 0.71) and OS (95% vs. 95%, p = 0.40).36